MetabolicPreliminary grade

CagriSema

Novo Nordisk's fixed-dose amylin + GLP-1 combo in phase-3 REDEFINE — up to 22% weight loss in early data.

Verdict — C · Emerging / Mixed

Additive amylin+GLP-1 mechanism with strong early data, but no approval and the REDEFINE-1 readout was mixed vs expectations in 2024. Gray-market material is unverifiable. A C pending a decisive phase-3 read.

PepScore / 100

CEmerging / Mixed

How we compute this →

Overview

CagriSema is a fixed-dose combination of cagrilintide (long-acting amylin analogue) and semaglutide 2.4 mg in phase-3 REDEFINE trials. Early phase-2 results showed approximately 15-22% weight loss, exceeding semaglutide alone. Neither component is approved as a combination, and no verified supply exists outside the clinical program.

PepScore Breakdown — the four axes

Evidence

35% weight

71/100

How strong is the published human science?

Human data depth28/40

Regulatory & registry status22/30

Reproducibility & consistency13/20

Mechanism characterized in humans8/10

Sourcing & COA

30% weightOur moat

38/100

Can a buyer obtain an independently-verified, high-purity version? — our proprietary layer.

Independent 3rd-party testing14/35

Verified purity %12/30

COA transparency & batch traceability7/20

Multi-vendor verified availability5/15

Safety & Risk

25% weight

47/100

What is the real-world harm potential?

Documented AEs / toxicity18/40

Contraindication breadth11/25

Regulatory warnings9/20

Therapeutic index / margin9/15

Practicality

10% weight

47/100

How easy is it to actually run a verified version?

Verified-source availability12/35

Cost / value per cycle11/25

Reconstitution & administration15/25

Storage & stability9/15

Sources & Citations

Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.

Want a clinical path?

Talk to a licensed provider about CagriSema and whether it's appropriate for your situation.

Talk to a Provider ↗

Telehealth. Not medical advice — for educational purposes.

PepScore53/100 · C

Last gradedJune 28, 2026

Next re-grade triggerREDEFINE-1/2 phase-3 approval would lift Evidence and Registry; a positive regulatory outcome would reshape Sourcing.

Price Index Vendor Grades Providers COA Lookup All Rankings

Get the PepEvolution Dispatch

Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.

Free. Unsubscribe anytime. Research/educational content only.

Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.